Abstract:Objective To identify the significance of genomic markers of drug sensitivity for individualized therapy in children with extracranial malignant solid tumors.Methods The surgical specimens and peripheral blood samples in 38 children with refractory extracranial malignant solid tumors were collected between Apri.2011 and Apri.2013.The genomic markers of anticancer drug sensitivity were examined,including gene expression or mutation of 15 chemotherapeutic agents and two targeted drugs by methods of immunohistochemical staining,enzyne linked immunosorbent assay,fluorescence in situ hybridization,polymerase chain reaction amplification and sequencing.Results Among all of 38 samples,35 were firstly surgical specimens and 3 secondary surgical specimens,and 3 of them were peripheral blood samples.The tumor tissue of the targets for chemotherapeutic agents such as topoisomerase Ⅱ A (TOPO Ⅱ A) in 34 cases,Tubulinβ3 in 32 cases,excision repair cross-complementing 1 (ERCC1) in 28 cases,topoisomerase Ⅰ (TOPO Ⅰ) in 28 cases,O6-methylguanine-DNA methyltransferase (MGMT) in 20 eases,thymidylate synthase (TS) in 13 cases and ribonucleotide reductase M 1 (RRM1)in 6 cases were examined.The 68.75％ samples were fluorouracil and pemetrexed sensitivity,66.67％ samples gemcitabine sensitivity,56.25％ samples vincristine(VCR) sensitivity;while 67.65％ had low sensitivity to anthracycline/etoposide,64.29％ had low sensitivity to platinum and topotecan/irinotecan;63.64％ had low sensitivity to temozolomide(TMZ).What's more,the peripheral blood of the targets for chemotherapeutic agents such as CYP2C9 * 3 genotypes in 33 cases and dihydrofolate reductase (DHFR C829T) genotypes in 14 cases were detected,and found that 100.00％ and 93.33％ of samples had cyclophosphamide and methotrexate sensitivity,respectively.Furthermore,peripheral blood was used to test the targets for chemotherapy toxicity and found that 100.00％ of cyclophosphamide and methotrexate toxicity were weak,76.19％ of irinotecan and etoposide toxicity was weak.Additionally,tumor tissues of the genomic markers for targeted drugs,such as vascular endothelial growth factor receptor-2 (VEGFR-2) in 15 cases,epidermal growth factor receptor (EGFR) in 5 cases and intercellular cell adhesion molecule-1 in 10 cases,were examined.Up to 68.00％ samples were detected sensitive to Bevacizumab.EGFR was not amplified in any case studied and Tyrosine kinase inhibitor response was invalid.On the basis of the above test results,therapeutic strategy for the patients who had unsatisfactory curative effect and then they achieved preliminary effect were promptly adjusted.Conclusions This study firstly examined the genomic markers of drug sensitivity in children with extracranial malignant solid tumors,which provide laboratory basis for individualized treatment selection and drug side effects prediction.

Primary Identification of Genomic Markers of Drug Sensitivity for Individualized Therapy in Children with Neuroblastoma of Ⅲ-Ⅳ Stage

Primary identification of genomic markers of drug sensitivity for individualized therapy in 38 children with extracranial malignant solid tumors

Individualized therapy for 58 children with refractory or relapsed malignant solid tumors based on the target detection of chemosensitivity

Comprehensive quantifications of tumour microenvironment to predict the responsiveness to immunotherapy and prognosis for paediatric neuroblastomas

Integrated Genomic Profiling and Drug Screening of Patient-Derived Cultures Identifies Individualized Copy Number-Dependent Susceptibilities Involving PI3K Pathway and 17q Genes in Neuroblastoma

A Single Center Clinical Analysis of Children with Neuroblastoma

A highly malignant case of neuroblastoma with substantial increase of single-nucleotide variants and normal mismatch repair system: A case report.

Systematic identification of genomic markers of drug sensitivity in cancer cells

Identification of novel prognostic markers of survival time in high-risk neuroblastoma using gene expression profiles

Analysis of Therapeuticresponse on Childhood Neuroblastoma with Multidisciplinary Therapy

Whole-Exome Sequencing Reveals Novel Candidate Driver Mutations and Potential Druggable Mutations in Patients with High-Risk Neuroblastoma

Bioinformatic Identification of Neuroblastoma Microenvironment-Associated Biomarkers with Prognostic Value

Higher tumor mutational burden is associated with inferior outcomes among pediatric patients with neuroblastoma

Identification of prognostic biomarkers in neuroblastoma using WGCNA and multi-omics analysis

MDB-38. COMPUTATIONAL DRUG SENSITIVITY PREDICTS MEDULLOBLASTOMA SUBGROUP-SPECIFIC THERAPEUTICS

Values of serum CA125, NSE and 24‐hour urine VMA in diagnosis and prediction of treatment of paediatric neuroblastoma

The relationship between circulating tumor cells in peripheral blood and clinical characteristics of pediatric neuroblastoma and prognostic evaluation

Annexin A2 Could Enhance Multidrug Resistance by Regulating NF-κB Signaling Pathway in Pediatric Neuroblastoma.

Individualized chemotherapy and efficacy analysis of hepatoblastoma in children

NCAPG is a Potential Biomarker for Prognosis of Treatment in Children with High-risk Neuroblastoma

Identification and External Validation of a Transcription Factor-Related Prognostic Signature in Pediatric Neuroblastoma